# TELA Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tela-bio

- Industry: Medical Devices & Equipment
- Headquarters: Malvern, US
- Website: www.telabio.com
- Total disclosed funding: $77M
- Latest round: Series B (Oct 25, 2017)
- Investors on record: 5

## About

TELA Bio, Inc. develops innovative surgical reconstruction solutions, primarily focusing on soft tissue repair through its flagship product OviTex®, designed to enhance healing while reducing synthetic material usage.Founded in 2012 and headquartered in Malvern, US, TELA Bio, Inc. specializes in surgical reconstruction solutions. Founded by Antony Koblish, who serves as the CEO, the company has completed 12 deals. The latest round of funding was a Private Placement which raised USD 32.00 mn. The total amount raised by the company is USD 32.00 mn, with the most recent deal date on November 8, 2019.TELA Bio specializes in innovative surgical reconstruction solutions, focusing primarily on the repair of soft tissue through its flagship product, OviTex®, a reinforced tissue matrix. OviTex incorporates layers of ovine rumen interwoven with polymer suture, designed to support the body’s natural healing processes while minimizing the use of synthetic materials. This product is intended for use in hernia and abdominal wall reconstruction, addressing the industry's shift away from traditional synthetic meshes due to concerns over long-term complications. The company’s product portfolio is tailored to meet the unique needs of patients, offering various resorption, stretch, and shape options within the OviTex PRS portfolio, which is specifically formulated for plastic and reconstructive surgery. TELA Bio targets various healthcare markets, primarily serving surgeons, hospitals, and healthcare institutions in North America and Europe, where there is a growing demand for advanced soft-tissue repair solutions.In the most recent year of 2024, TELA Bio generated revenue of USD 69.30 mn. The company reported an EBITDA of USD -33.10 mn.TELA Bio plans to leverage its recent funding, particularly the USD 32.00 mn raised in August 2022, to drive its growth initiatives. The company is working on expanding its product offerings with new designs of OviTex® aimed at enhancing surgical outcomes. Furthermore, TELA Bio seeks to penetrate new geographic markets in Asia and South America by 2025, capitalizing on the increasing demand for innovative surgical solutions.

## Funding rounds

- Series B, Oct 25, 2017, $15M — OrbiMed Advisors, Quaker Partners Management, Signet Healthcare Partners, Pacira Pharmaceuticals, Inc.
- Series B, Nov 20, 2014, $0.5M — OrbiMed Advisors
- Series B, Oct 8, 2014, $45M — Signet Healthcare Partners, Checkmate Capital
- Series A, Dec 6, 2012, $16M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series B
- Checkmate Capital (https://capitalatlas.ai/funds/checkmate-capital) — Series B
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series B
- Pacira Pharmaceuticals, Inc. — Series B